Old Web
English
Sign In
Acemap
>
authorDetail
>
Marc Ditmarsch
Marc Ditmarsch
AstraZeneca
Internal medicine
Medicine
Cardiology
Rosuvastatin
Diabetes mellitus
5
Papers
69
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
CETP-inhibitors: from HDL-C to LDL-C lowering agents?
2021
Cardiovascular Research
Nick S. Nurmohamed
Marc Ditmarsch
John J. P. Kastelein
Show All
Source
Cite
Save
Citations (0)
Abstract 16388: Efficacy and Safety of Early Dalcetrapib Treatment on Lipid Profile and Markers of HDL Functionality in Patients Hospitalized for an Acute Coronary Syndrome - The dal-ACUTE Study
2012
Circulation
Kausik K. Ray
Marc Ditmarsch
David Kallend
Gabriela Suchankova
Judith Anzures-Cabrera
Ruchi Upmanyu
Valerie Lehnert
Meike Pauly-Evers
Eric J. Niesor
Ingar Holme
Josef Stasek
Maarten W.J. Van Hessen
Peter H. Jones
Show All
Source
Cite
Save
Citations (0)
The MERCURY I open-label extension study — subgroup analysis in patients with diabetes
2008
The British Journal of Diabetes & Vascular Disease
Herbert Schuster
Mike K. Palmer
Marc Ditmarsch
Show All
Source
Cite
Save
Citations (5)
Effect of Short-Term Rosuvastatin Treatment on Estimated Glomerular Filtration Rate
2006
American Journal of Cardiology
Donald G. Vidt
Susan Harris
Fergus McTaggart
Marc Ditmarsch
Philip T. Sager
Jonathan M. Sorof
Show All
Source
Cite
Save
Citations (64)
W16-P-083 Rosuvastatin increases estimated glomerular filtration rate within 6–8 weeks of treatment
2005
Atherosclerosis Supplements
Jonathan M. Sorof
Susan Harris
Fergus McTaggart
Marc Ditmarsch
Philip T. Sager
Show All
Source
Cite
Save
Citations (0)
1